Locations:
Milestone case report expands understanding of infectious risks for those on immunomodulatory therapies
Phase 1 Breakfree-2 trial reports good safety and efficacy at week 26
Inflammatory protein eotaxin-1 may be a marker of future cognitive decline
Leading investigators outline a new roadmap for clinical trials and observational research
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
5-year funding award supports cohort expansion and deep phenotyping of AD and related dementias
New study aims to streamline dementia diagnoses and expand access to timely, accurate care
Routine capture of standardized neuroperformance data may expand and refine investigations
Free portal helps researchers classify and share data using the IC-CoDE framework
Recommendations on identifying and managing neurodevelopmental and related challenges
Cleveland Clinic researchers awarded $3.2 million for first-of-its-kind investigation
Advertisement
Advertisement
Search